{
    "title": "Aeterna hits record low after FDA rejects growth hormone test",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2823596/Aeterna-shares-halve-FDA-rejects-growth-hormone-test.html",
    "date": "2014-11-06",
    "keywords": [
        "percent",
        "growth",
        "companys",
        "record",
        "low",
        "test",
        "drug",
        "hormone",
        "trial",
        "macimorelin",
        "aeterna",
        "insulin",
        "muscle",
        "stock",
        "year",
        "gmt",
        "november",
        "email",
        "inc",
        "food",
        "administration",
        "drugmaker",
        "deficiencythe",
        "half",
        "analysis",
        "efficacy",
        "goal",
        "adult",
        "deficiency",
        "fda",
        "response",
        "letter",
        "agency",
        "involvement",
        "event",
        "effectiveness",
        "safety",
        "macimorelincanaccord",
        "genuity",
        "estimate",
        "success",
        "risk",
        "profile",
        "launch",
        "pathway",
        "macrilen",
        "time",
        "capital",
        "analyst",
        "noteaghd",
        "tolerance",
        "blood",
        "sugar",
        "body",
        "failure",
        "diagnosis",
        "aghdmacimorelin",
        "manner",
        "injectedaghd",
        "energy",
        "strength",
        "osteoporosis",
        "function",
        "use",
        "cachexia",
        "wasting",
        "loss",
        "weight",
        "massthe",
        "morning",
        "trading",
        "nasdaqcanaccord",
        "target",
        "start",
        "reporting",
        "grover",
        "bangalore",
        "editing",
        "savio",
        "dsouza"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}